JP2013517304A5 - - Google Patents

Download PDF

Info

Publication number
JP2013517304A5
JP2013517304A5 JP2012549215A JP2012549215A JP2013517304A5 JP 2013517304 A5 JP2013517304 A5 JP 2013517304A5 JP 2012549215 A JP2012549215 A JP 2012549215A JP 2012549215 A JP2012549215 A JP 2012549215A JP 2013517304 A5 JP2013517304 A5 JP 2013517304A5
Authority
JP
Japan
Prior art keywords
ranges
formulation
weight
amount
naproxen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012549215A
Other languages
English (en)
Japanese (ja)
Other versions
JP5975884B2 (ja
JP2013517304A (ja
Filing date
Publication date
Priority claimed from CA2690488A external-priority patent/CA2690488C/en
Application filed filed Critical
Publication of JP2013517304A publication Critical patent/JP2013517304A/ja
Publication of JP2013517304A5 publication Critical patent/JP2013517304A5/ja
Application granted granted Critical
Publication of JP5975884B2 publication Critical patent/JP5975884B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2012549215A 2010-01-19 2011-01-19 ソフトゲルカプセル化のためのナプロキセンの医薬処方およびその組合せ Active JP5975884B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CA2,690,488 2010-01-19
CA2690488A CA2690488C (en) 2010-01-19 2010-01-19 Pharmaceutical formulations of naproxen for soft gel encapsulation and combinations thereof
PCT/CA2011/000059 WO2011088553A1 (en) 2010-01-19 2011-01-19 Pharmaceutical formulations of naproxen for soft gel encapsulation and combinations thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016007253A Division JP2016094462A (ja) 2010-01-19 2016-01-18 ソフトゲルカプセル化のためのナプロキセンの医薬処方およびその組合せ

Publications (3)

Publication Number Publication Date
JP2013517304A JP2013517304A (ja) 2013-05-16
JP2013517304A5 true JP2013517304A5 (cg-RX-API-DMAC10.html) 2014-03-06
JP5975884B2 JP5975884B2 (ja) 2016-08-23

Family

ID=44303618

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2012549215A Active JP5975884B2 (ja) 2010-01-19 2011-01-19 ソフトゲルカプセル化のためのナプロキセンの医薬処方およびその組合せ
JP2016007253A Pending JP2016094462A (ja) 2010-01-19 2016-01-18 ソフトゲルカプセル化のためのナプロキセンの医薬処方およびその組合せ

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2016007253A Pending JP2016094462A (ja) 2010-01-19 2016-01-18 ソフトゲルカプセル化のためのナプロキセンの医薬処方およびその組合せ

Country Status (13)

Country Link
US (5) US9480667B2 (cg-RX-API-DMAC10.html)
EP (2) EP3909567B1 (cg-RX-API-DMAC10.html)
JP (2) JP5975884B2 (cg-RX-API-DMAC10.html)
AU (1) AU2011207061B2 (cg-RX-API-DMAC10.html)
CA (1) CA2690488C (cg-RX-API-DMAC10.html)
DK (1) DK2525789T3 (cg-RX-API-DMAC10.html)
ES (1) ES2880813T3 (cg-RX-API-DMAC10.html)
HU (1) HUE055771T2 (cg-RX-API-DMAC10.html)
MX (1) MX358636B (cg-RX-API-DMAC10.html)
PL (1) PL2525789T3 (cg-RX-API-DMAC10.html)
PT (1) PT2525789T (cg-RX-API-DMAC10.html)
SI (1) SI2525789T1 (cg-RX-API-DMAC10.html)
WO (1) WO2011088553A1 (cg-RX-API-DMAC10.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201301626D0 (en) 2013-01-30 2013-03-13 Dignity Sciences Ltd Composition comprising 15-OHEPA and methods of using the same
MX375328B (es) 2014-06-04 2025-03-06 Ds Biopharma Ltd Composiciones farmacéuticas que comprenden ácido dihomo-gamma-linolénico (dgla) y uso de las mismas
CN104083339A (zh) * 2014-08-04 2014-10-08 人福普克药业(武汉)有限公司 萘普生钠软胶囊及其制备方法
US10368284B2 (en) * 2014-11-12 2019-07-30 T-Mobile Usa, Inc. Quality of experience-based handover management
US10047033B2 (en) 2015-05-13 2018-08-14 Ds Biopharma Limited Compositions comprising oxo-derivatives of fatty acids and methods of making and using same
CN112245420A (zh) 2015-07-21 2021-01-22 艾菲穆恩有限公司 用于治疗或预防癌症和神经疾病的包括15-hepe的组合物
AU2016370626B2 (en) 2015-12-18 2020-08-20 Afimmune Limited Compositions comprising 15-HEPE and methods of using the same
CR20200552A (es) 2018-05-16 2021-05-13 Bayer Healthcare Llc Fórmula de suspención de alta concentración para medicamentos en cápsula de gel blanda paae resfriado y gripe
CN109692127A (zh) * 2019-03-15 2019-04-30 王征 一种密封小胶囊的制备方法
AU2020263295B2 (en) * 2019-04-26 2025-01-23 R.P. Scherer Technologies, Llc Mini softgel naproxen composition
US20210315851A1 (en) 2020-04-03 2021-10-14 Afimmune Limited Compositions comprising 15-hepe and methods of treating or preventing hematologic disorders, and/or related diseases
US20220233452A1 (en) * 2021-01-25 2022-07-28 R.P. Scherer Technologies, Llc Mini softgel naproxen composition

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA821577B (en) 1981-04-06 1983-03-30 Boots Co Plc Therapeutic agents
US4443428A (en) * 1982-06-21 1984-04-17 Euroceltique, S.A. Extended action controlled release compositions
US5071643A (en) * 1986-10-17 1991-12-10 R. P. Scherer Corporation Solvent system enhancing the solubility of pharmaceuticals for encapsulation
US5073371A (en) 1990-11-30 1991-12-17 Richardson-Vicks, Inc. Leave-on facial emulsion compositions
WO1995007103A1 (en) 1993-09-07 1995-03-16 The Procter & Gamble Company Compositions containing an amino acid salt of propionic acid non-steroidal anti-inflammatory agent and at least one of a decongestant, an expectorant, an antihistamine and an antitussive
US5484606A (en) * 1994-01-24 1996-01-16 The Procter & Gamble Company Process for reducing the precipitation of difficulty soluble pharmaceutical actives
AU706890B2 (en) * 1994-01-24 1999-07-01 Procter & Gamble Company, The Process for solubilizing difficultly soluble pharmaceutical actives
US5641512A (en) 1995-03-29 1997-06-24 The Procter & Gamble Company Soft gelatin capsule compositions
US6287594B1 (en) * 1998-01-20 2001-09-11 Edward S. Wilson Oral liquid compositions
US6383515B2 (en) * 1999-05-28 2002-05-07 Sawyer Maryjean Solvent system for enhancing solubility
US6387400B1 (en) 2000-08-29 2002-05-14 R.P. Scherer Technologies, Inc. Process for preparing pharmaceutical compositions for use with soft gelatin formulations
US20090318558A1 (en) * 2003-02-12 2009-12-24 Jae-Hwan Kim Solvent system of hardly soluble drug with improved dissolution rate
WO2004071490A1 (en) * 2003-02-12 2004-08-26 R & P Korea Co., Ltd. Solvent system of hardly soluble drug with improved elution rate
US20070053868A1 (en) * 2005-03-08 2007-03-08 Banner Pharmacaps, Inc. Solvent system for enhancing the solubility of pharmaceutical agents
US7582679B2 (en) 2006-02-03 2009-09-01 Pharmaceutics International Incorporated Compositions containing solid ibuprofen concentrates and methods of making solid ibuprofen concentrates
US20080014274A1 (en) * 2006-07-14 2008-01-17 Wyeth Enhanced stability phenylephrine liquid compositions
US20110052679A1 (en) * 2009-08-25 2011-03-03 Pharmaceutics International, Inc. Solid naproxen concentrates and related dosage forms

Similar Documents

Publication Publication Date Title
ES2913288T3 (es) Composiciones farmacéuticas que comprenden meloxicam
ES2562799T3 (es) Administración a velocidad modulada de fármacos desde un comprimido de tres capas que comprende tramadol, diclofenaco, paracetamol
MX2020011961A (es) Formas de dosis de liberacion controlada para substancias de farmaco de alta dosis, solubles en agua e higroscopicas.
ATE486593T1 (de) Feste dosierungsform mit einem wirkstoff mit unterdrücktem geschmack
JP2015038155A5 (cg-RX-API-DMAC10.html)
MX2015011896A (es) Formulacion de liberacion sostenida de mosapride que proporciona efectos farmacologicos y clinicos con administracion una vez al dia.
JP2009525343A5 (cg-RX-API-DMAC10.html)
AU2016238337A1 (en) Liquisoft capsules
ES2832565T3 (es) Composición farmacéutica que contiene celecoxib y tramadol
BR112012023324A2 (pt) processo de preparação de uma forma de dosagem multifásica liofilizada de dissolução rápida
AU2016208390A1 (en) Enhanced stability of novel liquid compositions
AR075735A1 (es) Composiciones farmaceuticas de liberacion inmediata que comprenden oxicodona y naloxona. uso
RU2014145557A (ru) Комбинированный состав, содержащий многокомпонентную сфероидальную таблетку (мкст), заключенную в твердую капсулу, и способ его приготовления
SI2729130T1 (en) Combined formulations of darunavir
WO2007075475A3 (en) Gastric reflux resistant dosage forms
JP2019530706A5 (cg-RX-API-DMAC10.html)
AR079174A1 (es) Composiciones para comprimidos desintegrables oralmente de ondansetron para prevenir nauseas y vomitos
JP2015514739A5 (cg-RX-API-DMAC10.html)
JP2015510928A5 (cg-RX-API-DMAC10.html)
CN103313704A (zh) 高度浓缩的液态对乙酰氨基酚溶液
US20210353574A1 (en) Softgels with solid or gel-like polymeric fill matrix
RU2015137612A (ru) Фармацевтическая дозированная лекарственная форма в виде мягкой желатиновой капсулы, содержащая модифицированную гуаровую камедь
JP2012505830A5 (cg-RX-API-DMAC10.html)
WO2011083402A3 (en) Immediate release compositions of acid labile drugs
JP2016512493A5 (cg-RX-API-DMAC10.html)